HEALTH

CVS Caremark appoints new president of PBM business

BY DSN STAFF

NEW YORK If there was any doubt as to the value CVS Caremark places on personalized medicine, that doubt no longer should exist.

Clearly, the company believes that one area its PBM can create real value for payers is within pharmacogenomics or personalized medicine. Not only has CVS Caremark tapped Per Lofberg, co-founder of genetic benefit management company Generation Health, to serve as the PBM president, but it also has upped its stake in Generation Health.

Generation Health will continue to operate as a separate business from CVS Caremark, but CVS Caremark will have financial and strategic ties to the company, as well as representation on its board of directors.

The moves are undoubtedly in line with CVS Caremark’s efforts to move well beyond a traditional retail pharmacy role and into a pharmacy healthcare service company aimed at improving health outcomes and lowering healthcare costs.

PGx clinical services are expected to be introduced to CVS Caremark’s PBM clients in the second quarter 2010, and will initially focus on testing programs for medications in the areas of oncology, cardiovascular medicine and HIV, among others. In addition, the partnership opens the door for future programs to test for certain hereditary diseases.

According to Generation Health, genomic testing represents a $3 billion market that is growing 45% annually. There are at least 100 new tests added each year and they are usually priced at several hundred dollars each.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

CRN adds new board members

BY Michael Johnsen

WASHINGTON The Council for Responsible Nutrition last week announced that the following executives have been elected to serve on the CRN board of directors, effective January — Chuck Brice of Kemin Health; Larry Esposito of Innophos; Ron Fugate of Alacer Corporation; Scott Hagerman of Chemi Nutra; Carl Hastings of Reliv International; and Vic Neufeld of Jamieson Laboratories.

In addition, Jim Hamilton of DSM Nutritional Products has been named CRN’s new chair-elect, replacing Janice Binger, formerly of Archer Daniels Midland.

“This has been a year of change for the dietary supplement industry, particularly with the shift of power in Washington,” stated Mark LeDoux, CRN chair. “Similarly the coming year will bring many challenges, but with those challenges comes the prospect of great opportunity.  CRN’s board of directors will strategically lead CRN to meet those challenges and pursue those opportunities both here and abroad.”

Following is a list of CRN’s board of directors, including Officers, for 2010:

  • Natalie Bartner, Pfizer Consumer Healthcare;
  • John Blair, NSA;
  • Kristen Blanchard, Nutramax Laboratories (secretary);
  • Paul Bolar, Pharmavite;
  • Michael Bradley, Perrigo Co.;
  • Chuck Brice, Kemin Health;
  • David Christensen, Bayer Healthcare (treasurer);
  • Greg Dodson, Archer Daniels Midland;
  • Larry Esposito, Innophos;
  • Marjorie Fine, Shaklee Corp.;
  • Ron Fugate, Alacer Corp.;
  • Scott Hagerman, Chemi Nutra;
  • Jim Hamilton, DSM Nutritional Products (chair-elect);
  • Carl Hastings, Reliv International; 
  • David Henstrom, Cargill Health & Nutrition;
  • Byron Johnson, Amway Corp.;
  • Harvey Kamil, NBTY;
  • Mark LeDoux, Natural Alternatives International (chair);
  • Doug Lioon, Douglas Laboratories;
  • Kathy McKnight, Natural Factors Nutritional Products;
  • Raj Mishra, GlaxoSmithKline;
  • Steve Mister, CRN (president & CEO);
  • David Morrison, The Vitamin Shoppe;
  • Vic Neufeld, Jamieson Laboratories;
  • Ona Scandurra, Country Life Vitamins;
  • Nick Shackley, BASF Corp.;
  • Robert Sinott, Mannatech;
  • Don Stanek, Linnea;
  • David Sullivan, GNC;
  • Bill Van Dyke, B&D Nutritional Ingredients;
  • John Venardos, Herbalife International of America;
  • Tyler Whitehead, NuSkin Enterprises; and
  • Bruce Wood, Schiff Nutrition International.

KelloggsDRSNhttp://www.centerstoregrowth.com

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

McNeil voluntarily recalls Tylenol Arthritis product

BY Michael Johnsen

FORT WASHINGTON, Pa. In consultation with the Food and Drug Administration, McNeil Consumer Healthcare on Friday expanded its voluntary recall to include all available product lots of Tylenol Arthritis Pain caplet 100-count bottles, with the distinctive red EZ-Open cap.

In November 2009, five lots of this product were recalled due to consumer reports of an unusual moldy, musty or mildew-like odor that was associated with nausea, stomach pain, vomiting and diarrhea. The recall is being expanded, as a precaution, to include all Tylenol Arthritis Pain caplet 100-count bottles with the distinctive red EZ-Open cap.

The uncharacteristic smell is caused by the presence of trace amounts of a chemical called 2,4,6-tribromoanisole. The source of 2,4,6-tribromoanisole is believed to be the breakdown of a chemical used to treat wooden pallets that transport and store packaging materials. The health effects of this compound have not been well studied, and to date all of the observed events reported to McNeil were temporary and non-serious.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES